Dronabinol

  • Dronabinol 1
  • Dronabinol 2
Product Description

Dronabinol is a phyto-derived Δ9-tetrahydrocannabinol active pharmaceutical ingredient isolated from Cannabis sativa L. Following GMP release testing of the starting material, it is purified through validated process steps to obtain a highly concentrated resinous product with an assay of at least 95.0 % Δ9-THC, manufactured in compliance with USP and DAC at our EU-GMP site in Schlattingen, Switzerland.

Appearance: colourless to pale yellow, highly viscous resin (heated for transfer), no significant odour. Controlled substance – supply subject to import/export permits. Current release specifications and technical batches available; DMF/ASMF under development.

Pack sizes: 100 g, 1 kg and 2.5 kg in wide-neck bottles; 250 mg to 5 g packs planned for 2027. Storage at or below 25 °C, protected from light. Detailed specification, example CoA and safety data sheet on request.

Read more Show less

Canexis Pharma AG

  • Country/Region:
    Switzerland
  • Founded:
    2020
  • On CPHI since:
    2025
  • Certificates:
    3
  • Employees:
    1 - 24
Company types
CMO/CDMO
Generics/Biosimilars Manufacturer
Manufacturer/Innovator
Pharmaceutical company
Primary activities
API Producer
Custom Manufacturing/Custom Synthesis
Generic APIs producer
Intermediates Manufacturer
Natural Extracts
View company profile
Categories
more categories Show less
Specifications
  • CAS Registry Number
    1972-08-3
  • Details
    Key specifications: Δ9-THC assay ≥ 95.0 %; exo-Δ9-THC ≤ 0.5 %; CBN ≤ 1.5 %; Δ8-THC ≤ 2.0 %; total impurities ≤ 5.0 %; water ≤ 0.5 %; sulfated ash ≤ 0.1 %; residual solvents n-pentane ≤ 5000 ppm; pesticides according to Ph. Eur. / EC 396/2005 / FAO-WHO; heavy metals As ≤ 0.2 ppm, Cd ≤ 0.3 ppm, Pb ≤ 0.5 ppm, Hg ≤ 0.1 ppm; mycotoxins total aflatoxins ≤ 4 µg/kg, ochratoxin A ≤ 20 µg/kg; microbiology TAMC ≤ 200 CFU/g, TYMC ≤ 20 CFU/g, specified pathogens absent.

    Application areas: pharmaceutical development and formulation of controlled medicinal products. Product type: phyto-derived pure cannabinoid API, single-cannabinoid resinous matrix. Compliance: USP / DAC. CAS 1972-08-3.
  • Selling Points
    International Approvals/Standards; Natural Ingredients; Place of Origin; Prompt Delivery; Quality Service; Small Orders Accepted; Manufactured in Switzerland under EU-GMP Part I and Part II licences, a Swissmedic manufacturing licence and a Swiss narcotics licence. Starting material from around ten qualified cultivation partners working to WHO-GACP, released under GMP against Ph. Eur.-based specifications. Release testing by qualified external GMP laboratories; Certificate of Analysis with every shipment. Technical/quality agreements, on-site audits, national regulatory documentation and DMF/ASMF support available. Shipping worldwide from Zurich Airport with temperature monitoring. Samples and technical batches on request.
  • Supplied from
    Switzerland
  • Measured In
    gram; kilogram
More specifications Fewer specifications
Sales Markets
Show more Show less

Canexis Pharma AG

  • Country/Region:
    Switzerland
  • Founded:
    2020
  • On CPHI since:
    2025
  • Certificates:
    3
  • Employees:
    1 - 24
Company types
CMO/CDMO
Generics/Biosimilars Manufacturer
Manufacturer/Innovator
Pharmaceutical company
Primary activities
API Producer
Custom Manufacturing/Custom Synthesis
Generic APIs producer
Intermediates Manufacturer
Natural Extracts
View company profile

More Products from Canexis Pharma AG (8)

  • Cannabidiol Ph. Eur.

    Product Cannabidiol Ph. Eur.

    Cannabidiol Ph. Eur. is a phyto-derived, highly purified cannabinoid active pharmaceutical ingredient isolated from Cannabis sativa L. and manufactured in accordance with the European Pharmacopoeia monograph for cannabidiol. After GMP release testing of the starting material, the product is purified and cr...
  • THCA (Tetrahydrocannabinolic acid)

    Product THCA (Tetrahydrocannabinolic acid)

    THCA (Δ9-tetrahydrocannabinolic acid) is the native, non-decarboxylated acid form of Δ9-THC found in Cannabis sativa L. Canexis isolates and purifies THCA from GMP-released cannabis starting material through validated extraction and purification steps at its EU-GMP site in Schlattingen, Switzerland, in the...
  • Cannabis Extract (THC)

    Product Cannabis Extract (THC)

    Cannabis Extract (THC) is derived from cannabis flowers in accordance with the European Pharmacopoeia monograph for cannabis flower. After receipt from qualified suppliers, the starting material is released under GMP and processed through a validated extraction route followed by two refinement steps that d...
  • Cannabis Extract (CBD)

    Product Cannabis Extract (CBD)

    Cannabis Extract (CBD) is derived from cannabis flowers in accordance with the European Pharmacopoeia. After GMP release testing of the starting material, it is processed through validated extraction, solvent-removal and decarboxylation steps at our EU-GMP site in Schlattingen, Switzerland. The result is a...
  • Cannabis Distillate (THC)

    Product Cannabis Distillate (THC)

    Cannabis Distillate (THC) is produced from cannabis-derived extract through an additional validated refining step using two-stage short-path distillation. The process removes most terpenes and pigments and yields a transparent orange-golden distillate with a THC-dominant profile and up to 95 % cannabinoids...
  • Cannabis Distillate (CBD)

    Product Cannabis Distillate (CBD)

    Cannabis Distillate (CBD) is produced through validated refinement of cannabis extract using short-path distillation. The process reduces terpenes and pigments and delivers a transparent yellow-golden to crystalline distillate with a CBD-dominant profile and up to 95 % cannabinoids. Depending on storage te...
  • Standardized Cannabis Extract Type I

    Product Standardized Cannabis Extract Type I

    Standardized Cannabis Extract Type I is prepared from validated Cannabis Extract (THC) and Cannabis Extract (CBD) and adjusted with medium-chain triglycerides (MCT) to the required cannabinoid profile. After GMP release testing of each starting material, the product is blended and controlled to deliver a t...
  • Standardized Cannabis Extract Type II

    Product Standardized Cannabis Extract Type II

    Standardized Cannabis Extract Type II is prepared from validated Cannabis Distillate (THC) and Cannabis Distillate (CBD) and adjusted with medium-chain triglycerides (MCT) to the required cannabinoid profile. The use of refined distillates provides a cleaner and more defined matrix and supports reproducibl...

Canexis Pharma AG resources (1)